Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
Status:
Terminated
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The study design includes a 3-dose randomization phase to determine effective doses of
INCB047986 in patients with myelodysplastic syndrome (MDS) who are refractory or unlikely to
respond to erythropoiesis-stimulating agents (ESAs) followed by an extension phase.